Blinatumomab (Blincyto® by Amgen) was the first CD19 targeting BiTE approved by the FDA for the treatment of B cell malignancies such as acute lymphoblastic leukemia (ALL) and for the treatment of patients experiencing minimal residual disease (MRD) [30]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.